Kevin A. Vest, PT, MBA, FACHE Joins Yale Cancer Center
I am delighted to welcome Kevin Vest as the Deputy Director for Clinical Affairs and Administration at Yale Cancer Center. Kevin joins Yale Cancer Center from Massachusetts General Hospital Cancer Center (MGHCC) where he served as Administrative Director for Hematology/Oncology and Finance. His experience with cancer center finances and operations, as well as program and service line development, will be integral to our success in the coming years.
Kevin holds an MBA in healthcare administration from Boston University and a BS in Physical Therapy from the University of Vermont. While at MGHCC, he also lectured at Boston University in their Doctorate of Physical Therapy Program. Kevin began his career in patient care as a physical therapist at Beth Israel Deaconess Medical Center.
As we approach the opening of Smilow Cancer Hospital at Yale-New Haven and increase our visibility as an NCI Comprehensive Cancer Center, I urge you to include your affiliation with both Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven when you submit manuscripts for publication and give presentations. YCC/SCH branded PowerPoint templates have been designed to ensure we have a consistent use of the two brands when making presentations. Please consider using them for your lectures.
Learn More >>
In recent days, four of the five MRIs that will be in Smilow were installed; one on the first floor, and three on the second floor. The fifth will be installed in the MR-OR on the third floor at a later date. In anticipation of an October opening, the contractor is now working on the punch-list for Radiation Oncology in the Lower Level.
Operational planning continues at the unit level, and on September 10th, the Operations Planning team will begin approving final "concepts of operations" for each unit.
The Education and Orientation team continues to develop all orientation materials. On August 18th, Moving Pictures Production Company spent the day in Smilow conducting interviews with Tom Lynch, MD, Abe Lopman, Sandy Cayo, RN, BSN, and patients for the orientation video.
received an R01 grant from the National Cancer Institute to use molecular techniques to select patients who will respond to treatment with Herceptin. Their research will help ensure that women with breast cancer who are not responsive to Herceptin are initially given an alternative therapy. The annual direct costs for the grant total $365,000.
During the International Association for the Study of Lung Cancer (IASLC) annual meeting earlier this month,
Dr. Thomas Lynch, Jr.
received the Scientific Award honoring his activities to support the IASLC mission and accomplishments in lung cancer research.
The American Society for Radiation Oncology (ASTRO) recognized
Sara Rockwell, PhD,
Professor of Therapeutic Radiology and Pharmacology, as one of 12 members of the 2009 class of ASTRO Fellows. Fellows must be members of ASTRO for at least 20 years, have served a leadership role in the organization, and have made a significant contribution to the field of radiation oncology.
Principal Investigator: Francine Foss, MD
An Open Label, Multi-Center, Dose Escalation, Phase I/II Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects with Previously Treated Peripheral T-Cell or Cutaneous T-cell Lymphoma
Principal Investigator: Kevin Kelly, DO
A Phase III, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer
The Mark I Cesium-137 irradiator is designed principally for biomedical research. Specific services of the Cesium-137 irradiator include irradiation of small animals such as rats, mice, hamsters, etc. in a controlled environment; irradiation of cell cultures, feeder layers, insects, bacteria, etc. in a temperature controlled, humidified or dry atmosphere of air and gases; sterilization of pharmaceuticals, medical appliances or laboratory apparatus; radiation chemistry reactions; and radiation dosimetry studies.
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.